Evidence map›Paper›PMID 40407908›Full record

ReviewCell biology and toxicology2025

Advancing oral cancer care: nanomaterial-driven diagnostic and therapeutic innovations.

Yuwen Chen, Sijia Cai, Fa-Yu Liu, Ming Liu

Abstract readReview
In one paragraph

Review in Cell biology and toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuwen ChenDepartmentof Orthodontics, School of Stomatology, China Medical University, 117 South Nanjing Street, Heping, Shenyang, Liaoning, 110002, P.R. China.
Sijia CaiDepartmentof Orthodontics, School of Stomatology, China Medical University, 117 South Nanjing Street, Heping, Shenyang, Liaoning, 110002, P.R. China.
Fa-Yu LiuDepartment of Oromaxillofacial-Head and Neck, Oral Maxillofacial Surgery, School of Stomatology, China Medical University, Shenyang, Liaoning, 110002, P.R. China.
Ming LiuDepartment of Oral Radiology, School of Stomatology, China Medical University, Shenyang, Liaoning, 110002, P.R. China. lm678876@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of nanotechnology has significantly advanced the diagnosis and treatment of oral cancer, offering more precise and efficient therapeutic strategies. This review presents a comprehensive overview of recent developments in the application of nanotechnology to oral cancer management. It begins with an overview of the epidemiology of oral cancer and outlines current diagnostic and therapeutic methods. The classification and advantages of various nanomaterials are then introduced. The paper thoroughly explores the use of nanomaterials as drug delivery systems (DDSs), imaging contrast agents, and therapeutic tools, with particular emphasis on multifunctional nanoplatforms that integrate diagnostics and therapy. These platforms enable real-time monitoring and immediate therapeutic response, offering innovative approaches for early detection and intervention. Despite these promising advances, several challenges persist, including issues related to biocompatibility, clearance, targeting specificity, and clinical translation. The review concludes by highlighting current limitations and proposing future directions for the clinical application of nanotechnology in oral cancer treatment.

Indexed as

Mouth NeoplasmsNanostructuresAnimalsContrast MediaDrug Delivery SystemsHumansNanotechnologyContrast MediaDrug carriersImaging contrast agentsIntegrated diagnosis and treatmentNanomaterialsOral cancerTherapeutic drugs

Identifiers

PMID40407908
PMCPMC12102110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.